Clinical Efficacy of Platelet-Rich Plasma in the Treatment of Neurotrophic Corneal Ulcer
Purpose. Platelet-rich plasma (PRP) is an autologous blood product without preservatives and rich in proteins and growth factors which make it possible for cells to differentiate, proliferate, and migrate, thus stimulating healing and regeneration of tissues. The aim of this study was to evaluate th...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2018/3538764 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552246089351168 |
|---|---|
| author | Dominika Wróbel-Dudzińska Jorge Alio Alejandra Rodriguez Ewa Suchodoła-Ratajewicz Ewa Kosior-Jarecka Beata Rymgayłło-Jankowska Agnieszka Ćwiklińska-Haszcz Tomasz Żarnowski |
| author_facet | Dominika Wróbel-Dudzińska Jorge Alio Alejandra Rodriguez Ewa Suchodoła-Ratajewicz Ewa Kosior-Jarecka Beata Rymgayłło-Jankowska Agnieszka Ćwiklińska-Haszcz Tomasz Żarnowski |
| author_sort | Dominika Wróbel-Dudzińska |
| collection | DOAJ |
| description | Purpose. Platelet-rich plasma (PRP) is an autologous blood product without preservatives and rich in proteins and growth factors which make it possible for cells to differentiate, proliferate, and migrate, thus stimulating healing and regeneration of tissues. The aim of this study was to evaluate the efficiency of autologous platelet-rich plasma in the treatment of neurotrophic keratopathy. Methods. The study group consists of 25 patients with nonhealing corneal ulcers due to herpes simplex or herpes zoster infection and facial nerve or trigeminal nerve paralysis as a result of a neurosurgical operation caused by a tumour or stroke. The patients were given autologous platelet-rich plasma drops five times a day and additionally preservative-free artificial tears and a vitamin A ointment at night for maximum 3 months. The following were evaluated: best corrected visual acuity (BCVA), healing of corneal surface, subjective symptoms, and changes in corneal thickness with the use of anterior segment optical coherent tomography (AS-OCT). Results. BCVA before the treatment was 0.10 ± 0.14, and after the treatment it was –0.3 ± 0.27 (p=0.001). Improved visual acuity and less subjective symptoms were observed in all patients. Complete healing of the ulceration was observed in 20 patients (80%). Four patients (16%) experienced considerable improvement of their clinical condition (reduced size and depth of the ulceration and inflammatory state: smaller conjunctival injection and swelling, improved visual acuity, and less subjective symptoms). In one of the patients, an amniotic membrane was transplanted due to the lack of improvement of his local condition. In all patients, the progression of corneal thinning was stopped. An average corneal thickness in its thinnest point was 322.3 ± 125.8 µm before the treatment, and 404.5 ± 118.7 µm (p<0.05) after the treatment. None of the patients reported general or local side effects of the treatment. Conclusions. Autologous platelet-rich plasma is a blood-based product which seems efficient in the treatment of neurotrophic keratopathy. |
| format | Article |
| id | doaj-art-af56ec195de94461a72d49e37da3ec73 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-af56ec195de94461a72d49e37da3ec732025-02-03T05:59:09ZengWileyJournal of Ophthalmology2090-004X2090-00582018-01-01201810.1155/2018/35387643538764Clinical Efficacy of Platelet-Rich Plasma in the Treatment of Neurotrophic Corneal UlcerDominika Wróbel-Dudzińska0Jorge Alio1Alejandra Rodriguez2Ewa Suchodoła-Ratajewicz3Ewa Kosior-Jarecka4Beata Rymgayłło-Jankowska5Agnieszka Ćwiklińska-Haszcz6Tomasz Żarnowski7Department of Diagnostics and Microsurgery of Glaucoma, Medical University of Lublin, Lublin, PolandDepartment of Cornea and Refractive Surgery, Vissum Corporation, Alicante, SpainResearch and Development Department, Vissum Corporation, Alicante, SpainDepartment of General Ophthalmology, Medical University of Lublin, Lublin, PolandDepartment of Diagnostics and Microsurgery of Glaucoma, Medical University of Lublin, Lublin, PolandDepartment of Diagnostics and Microsurgery of Glaucoma, Medical University of Lublin, Lublin, PolandDepartment of Diagnostics and Microsurgery of Glaucoma, Medical University of Lublin, Lublin, PolandDepartment of Diagnostics and Microsurgery of Glaucoma, Medical University of Lublin, Lublin, PolandPurpose. Platelet-rich plasma (PRP) is an autologous blood product without preservatives and rich in proteins and growth factors which make it possible for cells to differentiate, proliferate, and migrate, thus stimulating healing and regeneration of tissues. The aim of this study was to evaluate the efficiency of autologous platelet-rich plasma in the treatment of neurotrophic keratopathy. Methods. The study group consists of 25 patients with nonhealing corneal ulcers due to herpes simplex or herpes zoster infection and facial nerve or trigeminal nerve paralysis as a result of a neurosurgical operation caused by a tumour or stroke. The patients were given autologous platelet-rich plasma drops five times a day and additionally preservative-free artificial tears and a vitamin A ointment at night for maximum 3 months. The following were evaluated: best corrected visual acuity (BCVA), healing of corneal surface, subjective symptoms, and changes in corneal thickness with the use of anterior segment optical coherent tomography (AS-OCT). Results. BCVA before the treatment was 0.10 ± 0.14, and after the treatment it was –0.3 ± 0.27 (p=0.001). Improved visual acuity and less subjective symptoms were observed in all patients. Complete healing of the ulceration was observed in 20 patients (80%). Four patients (16%) experienced considerable improvement of their clinical condition (reduced size and depth of the ulceration and inflammatory state: smaller conjunctival injection and swelling, improved visual acuity, and less subjective symptoms). In one of the patients, an amniotic membrane was transplanted due to the lack of improvement of his local condition. In all patients, the progression of corneal thinning was stopped. An average corneal thickness in its thinnest point was 322.3 ± 125.8 µm before the treatment, and 404.5 ± 118.7 µm (p<0.05) after the treatment. None of the patients reported general or local side effects of the treatment. Conclusions. Autologous platelet-rich plasma is a blood-based product which seems efficient in the treatment of neurotrophic keratopathy.http://dx.doi.org/10.1155/2018/3538764 |
| spellingShingle | Dominika Wróbel-Dudzińska Jorge Alio Alejandra Rodriguez Ewa Suchodoła-Ratajewicz Ewa Kosior-Jarecka Beata Rymgayłło-Jankowska Agnieszka Ćwiklińska-Haszcz Tomasz Żarnowski Clinical Efficacy of Platelet-Rich Plasma in the Treatment of Neurotrophic Corneal Ulcer Journal of Ophthalmology |
| title | Clinical Efficacy of Platelet-Rich Plasma in the Treatment of Neurotrophic Corneal Ulcer |
| title_full | Clinical Efficacy of Platelet-Rich Plasma in the Treatment of Neurotrophic Corneal Ulcer |
| title_fullStr | Clinical Efficacy of Platelet-Rich Plasma in the Treatment of Neurotrophic Corneal Ulcer |
| title_full_unstemmed | Clinical Efficacy of Platelet-Rich Plasma in the Treatment of Neurotrophic Corneal Ulcer |
| title_short | Clinical Efficacy of Platelet-Rich Plasma in the Treatment of Neurotrophic Corneal Ulcer |
| title_sort | clinical efficacy of platelet rich plasma in the treatment of neurotrophic corneal ulcer |
| url | http://dx.doi.org/10.1155/2018/3538764 |
| work_keys_str_mv | AT dominikawrobeldudzinska clinicalefficacyofplateletrichplasmainthetreatmentofneurotrophiccornealulcer AT jorgealio clinicalefficacyofplateletrichplasmainthetreatmentofneurotrophiccornealulcer AT alejandrarodriguez clinicalefficacyofplateletrichplasmainthetreatmentofneurotrophiccornealulcer AT ewasuchodołaratajewicz clinicalefficacyofplateletrichplasmainthetreatmentofneurotrophiccornealulcer AT ewakosiorjarecka clinicalefficacyofplateletrichplasmainthetreatmentofneurotrophiccornealulcer AT beatarymgayłłojankowska clinicalefficacyofplateletrichplasmainthetreatmentofneurotrophiccornealulcer AT agnieszkacwiklinskahaszcz clinicalefficacyofplateletrichplasmainthetreatmentofneurotrophiccornealulcer AT tomaszzarnowski clinicalefficacyofplateletrichplasmainthetreatmentofneurotrophiccornealulcer |